• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Breast cancer specialists' views on and use of risk prediction models in clinical practice: a mixed methods approach.乳腺癌专家对风险预测模型在临床实践中的看法及应用:一种混合方法研究
Acta Oncol. 2015 Mar;54(3):361-7. doi: 10.3109/0284186X.2014.964810. Epub 2014 Oct 13.
2
Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists.老年HER-2阳性乳腺癌患者辅助化疗和曲妥珠单抗使用的观点与态度:肿瘤学家调查
Oncologist. 2009 Sep;14(9):883-90. doi: 10.1634/theoncologist.2009-0056. Epub 2009 Sep 2.
3
Adjuvant chemotherapy in node negative breast cancer: patterns of use and oncologists' preferences.
Ann Oncol. 2000 May;11(5):631-3. doi: 10.1023/a:1008379628579.
4
Generalists and oncologists show similar care practices and outcomes for hospitalized late-stage cancer patients. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks for Treatment.对于住院的晚期癌症患者,全科医生和肿瘤学家的护理方式及治疗效果相似。支持性治疗研究组。了解预后及对治疗结果和风险的偏好的研究。
Med Care. 2000 Nov;38(11):1103-18. doi: 10.1097/00005650-200011000-00005.
5
Oncologists' opinions towards recommending exercise to patients with cancer: a Canadian national survey.肿瘤学家对向癌症患者推荐运动的看法:一项加拿大全国性调查。
Support Care Cancer. 2005 Nov;13(11):929-37. doi: 10.1007/s00520-005-0805-8. Epub 2005 Sep 27.
6
Treatment recommendations for older women with breast cancer: A survey among surgical, radiation and medical oncologists.老年乳腺癌女性的治疗建议:外科、放疗及肿瘤内科医生的一项调查
Eur J Surg Oncol. 2017 Jul;43(7):1288-1296. doi: 10.1016/j.ejso.2017.02.006. Epub 2017 Feb 20.
7
Patient surveillance after initial breast cancer therapy: variation by physician specialty.初始乳腺癌治疗后的患者监测:按医师专业的差异。
Am J Surg. 2013 Aug;206(2):218-22. doi: 10.1016/j.amjsurg.2012.05.037.
8
Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status.肿瘤学家对不同年龄和健康状况的激素受体阳性乳腺癌患者辅助治疗的建议。
Clin Breast Cancer. 2010 Apr;10(2):136-43. doi: 10.3816/CBC.2010.n.018.
9
Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models.预测和交流早期乳腺癌女性复发和死亡风险:风险预测模型的系统评价。
J Clin Oncol. 2014 Jan 20;32(3):238-50. doi: 10.1200/JCO.2013.50.3417. Epub 2013 Dec 16.
10
Oncologists' recognition of supportive care needs and symptoms of their patients in a breast cancer outpatient consultation.肿瘤医生在乳腺癌门诊就诊中对患者支持性照护需求及症状的识别。
Jpn J Clin Oncol. 2011 Nov;41(11):1251-8. doi: 10.1093/jjco/hyr146. Epub 2011 Oct 13.

引用本文的文献

1
Risk-Prediction Models for Clinical Decision-Making in Sarcoma Care: An International Survey Among Soft-Tissue Sarcoma Clinicians.肉瘤治疗中临床决策的风险预测模型:一项针对软组织肉瘤临床医生的国际调查
Ann Surg Oncol. 2025 Apr;32(4):2958-2970. doi: 10.1245/s10434-024-16849-7. Epub 2025 Feb 1.
2
Improving shared decision-making about cancer treatment through design-based data-driven decision-support tools and redesigning care paths: an overview of the 4D PICTURE project.通过基于设计的数据驱动决策支持工具和重新设计护理路径来改善癌症治疗的共同决策:4D PICTURE项目概述
Palliat Care Soc Pract. 2024 Feb 12;18:26323524231225249. doi: 10.1177/26323524231225249. eCollection 2024.
3
(Cost-)effectiveness of an individualised risk prediction tool (PERSARC) on patient's knowledge and decisional conflict among soft-tissue sarcomas patients: protocol for a parallel cluster randomised trial (the VALUE-PERSARC study).个体化风险预测工具(PERSARC)对软组织肉瘤患者知识和决策冲突的成本效益:一项平行聚类随机试验的方案(VALUE-PERSARC 研究)。
BMJ Open. 2023 Nov 2;13(11):e074853. doi: 10.1136/bmjopen-2023-074853.
4
A nomogram for individually predicting overall survival for elderly patients with early breast cancer: a consecutive cohort study.一项用于个体化预测老年早期乳腺癌患者总生存期的列线图:一项连续队列研究。
Front Oncol. 2023 Jul 28;13:1189551. doi: 10.3389/fonc.2023.1189551. eCollection 2023.
5
Discussing personalized prognosis in amyotrophic lateral sclerosis: development of a communication guide.探讨肌萎缩侧索硬化症的个体化预后:沟通指南的制定。
BMC Neurol. 2020 Dec 14;20(1):446. doi: 10.1186/s12883-020-02004-8.
6
How to optimize the design and implementation of risk prediction tools: focus group with patients with IgA nephropathy.如何优化风险预测工具的设计和实施:与 IgA 肾病患者的焦点小组。
BMC Med Inform Decis Mak. 2020 Sep 16;20(1):231. doi: 10.1186/s12911-020-01253-4.
7
A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management.基于信息价值的乳腺癌管理 21 基因检测研究分析。
Value Health. 2019 Oct;22(10):1102-1110. doi: 10.1016/j.jval.2019.05.004. Epub 2019 Aug 7.
8
Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.乳腺癌 21 基因检测的成本效益分析:系统评价与关键评估。
J Clin Oncol. 2018 Jun 1;36(16):1619-1627. doi: 10.1200/JCO.2017.76.5941. Epub 2018 Apr 16.
9
Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer.早期乳腺癌辅助化疗的预后和预测因素。
Indian J Med Res. 2017 Nov;146(5):563-571. doi: 10.4103/ijmr.IJMR_1354_17.
10
Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries.BOADICEA网络应用程序在临床实践中的应用:各国临床医生的评估
Fam Cancer. 2018 Jan;17(1):31-41. doi: 10.1007/s10689-017-0014-x.

本文引用的文献

1
Helping Doctors and Patients Make Sense of Health Statistics.帮助医生和患者理解健康统计数据。
Psychol Sci Public Interest. 2007 Nov;8(2):53-96. doi: 10.1111/j.1539-6053.2008.00033.x. Epub 2007 Nov 1.
2
Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models.预测和交流早期乳腺癌女性复发和死亡风险:风险预测模型的系统评价。
J Clin Oncol. 2014 Jan 20;32(3):238-50. doi: 10.1200/JCO.2013.50.3417. Epub 2013 Dec 16.
3
Why do single event probabilities confuse patients?为什么单事件概率会让患者感到困惑?
BMJ. 2012 Jan 11;344:e245. doi: 10.1136/bmj.e245.
4
Does use of the adjuvant! model influence use of adjuvant therapy through better risk communication?辅助! 模型的使用是否通过更好的风险沟通影响辅助治疗的使用?
J Natl Compr Canc Netw. 2011 Jul 1;9(7):707-12. doi: 10.6004/jnccn.2011.0061.
5
Adjuvant! Online as a decision-making tool in early breast cancer--a UK national survey.
Clin Oncol (R Coll Radiol). 2011 Mar;23(2):159-60. doi: 10.1016/j.clon.2010.11.004. Epub 2010 Nov 26.
6
Communication of uncertainty regarding individualized cancer risk estimates: effects and influential factors.不确定性沟通与个体化癌症风险估计:影响因素及效果。
Med Decis Making. 2011 Mar-Apr;31(2):354-66. doi: 10.1177/0272989X10371830. Epub 2010 Jul 29.
7
Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis.肿瘤学家对辅助治疗!模型用于风险沟通的应用:一项检验患者对10年预后了解情况的试点研究。
BMC Cancer. 2009 Apr 28;9:127. doi: 10.1186/1471-2407-9-127.
8
Improving understanding of adjuvant therapy options by using simpler risk graphics.通过使用更简单的风险图表来提高对辅助治疗方案的理解。
Cancer. 2008 Dec 15;113(12):3382-90. doi: 10.1002/cncr.23959.
9
Communicating the uncertainty of harms and benefits of medical interventions.传达医疗干预措施危害与益处的不确定性。
Med Decis Making. 2007 Sep-Oct;27(5):681-95. doi: 10.1177/0272989X07307270. Epub 2007 Sep 14.
10
Informed decision making in outpatient practice: time to get back to basics.门诊实践中的明智决策:回归基础的时候了。
JAMA. 1999;282(24):2313-20. doi: 10.1001/jama.282.24.2313.

乳腺癌专家对风险预测模型在临床实践中的看法及应用:一种混合方法研究

Breast cancer specialists' views on and use of risk prediction models in clinical practice: a mixed methods approach.

作者信息

Engelhardt Ellen G, Pieterse Arwen H, van Duijn-Bakker Nanny, Kroep Judith R, de Haes Hanneke C J M, Smets Ellen M A, Stiggelbout Anne M

机构信息

Department of Medical Decision Making, Leiden University Medical Center , Leiden , The Netherlands.

出版信息

Acta Oncol. 2015 Mar;54(3):361-7. doi: 10.3109/0284186X.2014.964810. Epub 2014 Oct 13.

DOI:10.3109/0284186X.2014.964810
PMID:25307407
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4445013/
Abstract

PURPOSE

Risk prediction models (RPM) in breast cancer quantify survival benefit from adjuvant systemic treatment. These models [e.g. Adjuvant! Online (AO)] are increasingly used during consultations, despite their not being designed for such use. As still little is known about oncologists' views on and use of RPM to communicate prognosis to patients, we investigated if, why, and how they use RPM.

METHODS

We disseminated an online questionnaire that was based on the literature and individual and group interviews with oncologists.

RESULTS

Fifty-one oncologists (partially) completed the questionnaire. AO is the best known (95%) and most frequently used RPM (96%). It is used to help oncologists decide whether or not to recommend chemotherapy (>85%), to inform (86%) and help patients decide about treatment (>80%), or to persuade them to follow the proposed course of treatment (74%). Most oncologists (74%) believe that using AO helps patients understand their prognosis.

CONCLUSION

RPM have found a place in daily practice, especially AO. Oncologists think that using AO helps patients understand their prognosis, yet studies suggest that this is not always the case. Our findings highlight the importance of exploring whether patients understand the information that RPM provide.

摘要

目的

乳腺癌风险预测模型(RPM)可量化辅助性全身治疗的生存获益。这些模型[如辅助治疗在线(AO)]越来越多地在会诊中使用,尽管其并非为此用途而设计。由于对于肿瘤学家在使用RPM向患者传达预后方面的观点和使用情况仍知之甚少,我们调查了他们是否使用、为何使用以及如何使用RPM。

方法

我们分发了一份基于文献以及对肿瘤学家进行的个人和小组访谈的在线问卷。

结果

51名肿瘤学家(部分)完成了问卷。AO是最知名的(95%)且最常使用的RPM(96%)。它用于帮助肿瘤学家决定是否推荐化疗(>85%)、为患者提供信息(86%)并帮助患者决定治疗方案(>80%)或说服他们遵循提议的治疗方案(74%)。大多数肿瘤学家(74%)认为使用AO有助于患者了解其预后。

结论

RPM在日常实践中已占有一席之地,尤其是AO。肿瘤学家认为使用AO有助于患者了解其预后,但研究表明情况并非总是如此。我们的研究结果凸显了探究患者是否理解RPM所提供信息的重要性。